Total raised
—
Last: Pre-Seed 2022-01
Stage
Pre-Seed
Founded
2022
Headcount
5
HQ
Nazareth
Sector
Health Tech & Life Sciences
About
I-Derm Pharma is developing a first-in-class oral therapy for moderate-to-severe psoriasis. Our proprietary small-molecule family targets an inflammatory pathway and has shown strong preclinical efficacy in chimeric mice with psoriatic human skin grafts, alongside a favorable safety profile. We are advancing our lead candidate toward IND with robust IP and are preparing for next milestones and strategic collaborations.
Funding history · 1 round · — total
2022-01
Pre-Seed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife Sciences
Business model
B2B2C
Highlights
1 PatentsVerified
Tags
dermatologypharmaceuticalsautoimmune-diseasesoral-drugs